T he BIOSTAT-CHF (BIOlogy Study to TAilored Treatment in Chronic Heart Failure) study by Bayes-Genis et al. (1) in this issue of the Journal describes the prognostic value of a new biotarget in the management of atherosclerosis progression: the proprotein convertase subtilisin/kexin type 9 (PCSK9), and its interaction or “axis” with low-density lipoprotein receptors (LDLRs) on the surface of hepatocytes. Although it is well known that PCSK9 and LDLR are associated with atherosclerotic risk (2), the interaction of cholesterol and the clinical syndrome of heart failure are unclear. To date, large-scale trials have not confirmed a firm across-the-board benefit of statins for the treatment of congestive heart failure. The relation of PCSK9 and LDLR to heart failure has not previously been explored, and very little is known regarding how PCSK9 and LDLR may relate to future heart failure events.

中文翻译：

---

胆固醇和心力衰竭

Bayes-Genis 等人的 BIOSTAT-CHF（慢性心力衰竭定制治疗的生物学研究）研究。(1) 在本期杂志中，描述了一种新的生物靶点在动脉粥样硬化进展管理中的预后价值：前蛋白转化酶枯草杆菌蛋白酶 / kexin 9 型（PCSK9），及其与低密度脂蛋白受体的相互作用或“轴”（ LDLR）在肝细胞表面。尽管众所周知 PCSK9 和 LDLR 与动脉粥样硬化风险有关 (2)，但胆固醇与心力衰竭临床综合征的相互作用尚不清楚。迄今为止，大规模试验尚未证实他汀类药物治疗充血性心力衰竭的全面益处。PCSK9 和 LDLR 与心力衰竭的关系以前没有被探索过，